An insight from computational approach to explore novel, high-affinity phosphodiesterase 10A inhibitors for neurological disorders

References

• Abdel-Magid, A. F. (2018). Potential of PDE10A inhibitors as treatment for schizophrenia and other neurological disorders. Acs Medicinal Chemistry Letters, 9(9), 866–867. https://doi.org/10.1021/acsmedchemlett.8b00341
   PubMedGoogle Scholar
• Al-Nema, M., Gaurav, A., Lee, V. S., Gunasekaran, B., Lee, M. T., Okechukwu, P., & NimmaNPipug, P. (2022). Structure-based discovery and bio-evaluation of a cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one as a phosphodiesterase 10A inhibitor. RSC Advances, 12(3), 1576–1591. https://doi.org/10.1039/D1RA07649C
   PubMed Web of Science ®Google Scholar
• Amin, H. S., Parikh, P. K., & Ghate, M. D. (2021). Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors – An update of recent progress. European Journal of Medicinal Chemistry, 214, 113155. https://doi.org/10.1016/J.EJMECH.2021.113155
   PubMed Web of Science ®Google Scholar
• Arthur, D. E., & Uzairu, A. (2019). Molecular docking studies on the interaction of NCI anticancer analogues with human Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit. Journal of King Saud University – Science, 31(4), 1151–1166. https://doi.org/10.1016/j.jksus.2019.01.011
   Web of Science ®Google Scholar
• Azevedo, M. F., Faucz, F. R., Bimpaki, E., Horvath, A., Levy, I., De Alexandre, R. B., Ahmad, F., Manganiello, V., & Stratakis, C. A. (2014). Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocrine Reviews, 35(2), 195–233. https://doi.org/10.1210/ER.2013-1053
   PubMed Web of Science ®Google Scholar
• Bhardwaj, V. K., & Purohit, R. (2021). Computer simulation to identify selective inhibitor for human phosphodiesterase10A. Journal of Molecular Liquids, 328, 115419. https://doi.org/10.1016/j.molliq.2021.115419
   Web of Science ®Google Scholar
• Bhattacherjee, D., Kovalev, I. S., Kopchuk, D. S., Rahman, M., Santra, S., Zyryanov, G. V., Das, P., Purohit, R., Rusinov, V. L., & Chupakhin, O. N. (2022). Cu salts-free mechanochemical approach towards multi-functionalized 1,2,3-triazoles and anti-seizure drug rufinamide analogs. https://doi.org/10.26434/CHEMRXIV-2022-50C3J
   Google Scholar
• Boswell-Smith, V., Spina, D., & Page, C. P. (2006). Phosphodiesterase inhibitors. British Journal of Pharmacology, 147(S1), S252–S257. https://doi.org/10.1038/sj.bjp.0706495
   PubMed Web of Science ®Google Scholar
• Chappie, T. A., Helal, C. J., & Hou, X. (2012). Current landscape of phosphodiesterase 10A (PDE10A) inhibition. Journal of Medicinal Chemistry, 55(17), 7299–7331. https://doi.org/10.1021/JM3004976
   PubMed Web of Science ®Google Scholar
• Chappie, T. A., Humphrey, J. M., Allen, M. P., Estep, K. G., Fox, C. B., Lebel, L. A., Liras, S., Marr, E. S., Menniti, F. S., Pandit, J., Schmidt, C. J., Tu, M., Williams, R. D., & Yang, F. V. (2007). Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. Journal of Medicinal Chemistry, 50(2), 182–185. https://doi.org/10.1021/JM060653B/SUPPL_FILE/JM060653BSI20061129_015143.PDF
   PubMed Web of Science ®Google Scholar
• Chen, D., Oezguen, N., Urvil, P., Ferguson, C., Dann, S. M., & Savidge, T. C. (2016). Regulation of protein-ligand binding affinity by hydrogen bond pairing. Science Advances, 2(3), e1501240. https://doi.org/10.1126/sciadv.1501240
   Web of Science ®Google Scholar
• Chen, J., Wang, J., & Zhu, W. (2017a). Zinc ion-induced conformational changes in new Delphi metallo-β-lactamase 1 probed by molecular dynamics simulations and umbrella sampling. Physical Chemistry Chemical Physics: PCCP, 19(4), 3067–3075. https://doi.org/10.1039/C6CP08105C
   PubMed Web of Science ®Google Scholar
• Chen, J., Wang, J., & Zhu, W. (2017b). Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling. Physical Chemistry Chemical Physics: PCCP, 19(44), 30239–30248. https://doi.org/10.1039/C7CP05418A
   PubMed Web of Science ®Google Scholar
• Conti, M., & Beavo, J. (2007). Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annual Review of Biochemistry, 76, 481–511. https://doi.org/10.1146/ANNUREV.BIOCHEM.76.060305.150444
   PubMed Web of Science ®Google Scholar
• de Souza, O. N., & Ornstein, R. L. (1999). Molecular dynamics simulations of a protein-protein dimer: Particle-mesh Ewald electrostatic model yields far superior results to standard cutoff model. Journal of Biomolecular Structure & Dynamics, 16(6), 1205–1218. https://doi.org/10.1080/07391102.1999.10508328
   PubMed Web of Science ®Google Scholar
• Erro, R., Mencacci, N. E., & Bhatia, K. P. (2021). The emerging role of phosphodiesterases in movement disorders. Movement Disorders, 36(10), 2225–2243. https://doi.org/10.1002/MDS.28686
   PubMed Web of Science ®Google Scholar
• Francis, S. H., Blount, M. A., & Corbin, J. D. (2011). Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiological Reviews, 91(2), 651–690. https://doi.org/10.1152/PHYSREV.00030.2010
   PubMed Web of Science ®Google Scholar
• Gaussian, M. F. (2016). Gaussian 16. Gaussian, Inc.
   Google Scholar
• Grauer, S. M., Pulito, V. L., Navarra, R. L., Kelly, M. P., Kelley, C., Graf, R., Langen, B., Logue, S., Brennan, J., Jiang, L., Charych, E., Egerland, U., Liu, F., Marquis, K. L., Malamas, M., Hage, T., Comery, T. A., & Brandon, N. J. (2009). Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of Schizophrenia. The Journal of Pharmacology and Experimental Therapeutics, 331(2), 574–590. https://doi.org/10.1124/JPET.109.155994
   PubMed Web of Science ®Google Scholar
• Guleria, V., Pal, T., Sharma, B., Chauhan, S., & Jaiswal, V. (2021). Pharmacokinetic and molecular docking studies to design antimalarial compounds targeting Actin I. International Journal of Health Sciences, 15(6), 4–15. /pmc/articles/PMC8589829/
   Google Scholar
• Helal, C. J., Kang, Z., Hou, X., Pandit, J., Chappie, T. A., HumphRey, J. M., Marr, E. S., Fennell, K. F., Chenard, L. K., Fox, C., Schmidt, C. J., Williams, R. D., Chapin, D. S., Siuciak, J., Lebel, L., Menniti, F., Cianfrogna, J., Fonseca, K. R., Nelson, F. R., … Liras, S. (2011). Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia. Journal of Medicinal Chemistry, 54(13), 4536–4547. https://doi.org/10.1021/JM2001508/SUPPL_FILE/JM2001508_SI_001.PDF
   PubMed Web of Science ®Google Scholar
• Höfgen, N., Stange, H., Schindler, R., Lankau, H. J., Grunwald, C., Langen, B., Egerland, U., Tremmel, P., Pangalos, M. N., Marquis, K. L., Hage, T., Harrison, B. L., Malamas, M. S., Brandon, N. J., & Kronbach, T. (2010). Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors. Journal of Medicinal Chemistry, 53(11), 4399–4411. https://doi.org/10.1021/JM1002793
   PubMed Web of Science ®Google Scholar
• Jäger, R., Russwurm, C., Schwede, F., Genieser, H. G., Koesling, D., & Russwurm, M. (2012). Activation of PDE10 and PDE11 phosphodiesterases. The Journal of Biological Chemistry, 287(2), 1210–1219. https://doi.org/10.1074/JBC.M111.263806
   PubMed Web of Science ®Google Scholar
• Jansen, C., Kooistra, A. J., Kanev, G. K., Leurs, R., De Esch, I., J. P., & De Graaf, C. (2016). PDEStrIAn: A phosphodiesterase structure and ligand interaction annotated database as a tool for structure-based drug design. Journal of Medicinal Chemistry, 59(15), 7029–7065. https://doi.org/10.1021/ACS.JMEDCHEM.5B01813/SUPPL_FILE/JM5B01813_SI_001.ZIP
   PubMed Web of Science ®Google Scholar
• Kehler, J., & Nielsen, J. (2011). PDE10A inhibitors: Novel therapeutic drugs for Schizophrenia. Current Pharmaceutical Design, 17(2), 137–150. https://doi.org/10.2174/138161211795049624
   PubMed Web of Science ®Google Scholar
• Kleiman, R. J., Kimmel, L. H., Bove, S. E., Lanz, T. A., Harms, J. F., Romegialli, A., Miller, K. S., Willis, A., Des Etages, S., Kuhn, M., & Schmidt, C. J. (2011). Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington’s disease. The Journal of Pharmacology and Experimental Therapeutics, 336(1), 64–76. https://doi.org/10.1124/JPET.110.173294
   PubMed Web of Science ®Google Scholar
• Kumar Bhardwaj, V., Das, P., & Purohit, R. (2022). Identification and comparison of plant-derived scaffolds as selective CDK5 inhibitors against standard molecules: Insights from umbrella sampling simulations. Journal of Molecular Liquids, 348, 118015. https://doi.org/10.1016/j.molliq.2021.118015
   Web of Science ®Google Scholar
• Kumar, S., Bhardwaj, V. K., Singh, R., Das, P., & Purohit, R. (2022). Evaluation of plant-derived semi-synthetic molecules against BRD3-BD2 protein: A computational strategy to combat breast cancer. Molecular Systems Design & Engineering, 7(4), 381–391. https://doi.org/10.1039/D1ME00183C
   Web of Science ®Google Scholar
• Kumari, R., Kumar, R., & Lynn, A. (2014). G-mmpbsa – A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/10.1021/CI500020M/SUPPL_FILE/CI500020M_SI_001.PDF
   PubMed Web of Science ®Google Scholar
• Lagorce, D., Douguet, D., Miteva, M. A., & Villoutreix, B. O. (2017). Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors. Scientific reports, 7(1),46277–15. https://doi.org/10.1038/srep46277
   PubMedGoogle Scholar
• Le, L., Lee, E. H., Hardy, D. J., Truong, T. N., & Schulten, K. (2010). Molecular dynamics simulations suggest that electrostatic funnel directs binding of tamiflu to influenza N1 neuraminidases. PLoS Computational Biology, 6(9), e1000939. https://doi.org/10.1371/journal.pcbi.1000939
   PubMed Web of Science ®Google Scholar
• Lesitha Jeeva Kumari, J., Jesu Jaya Sudan, R., & Sudandiradoss, C. (2017). Evaluation of peptide designing strategy against subunit reassociation in mucin 1: A steered molecular dynamics approach. PloS One, 12(8), e0183041. https://doi.org/10.1371/JOURNAL.PONE.0183041
   PubMed Web of Science ®Google Scholar
• Li, Z., Fichthorn, K. A., & Milner, S. T. (2016). Surfactant binding to polymer-water interfaces in atomistic simulations. Langmuir: The ACS Journal of Surfaces and Colloids, 32(30), 7519–7529. https://doi.org/10.1021/ACS.LANGMUIR.6B01393/SUPPL_FILE/LA6B01393_SI_003.PDF
   PubMed Web of Science ®Google Scholar
• Mai, B. K., & Li, M. S. (2011). Neuraminidase inhibitor R-125489 – A promising drug for treating influenza virus: Steered molecular dynamics approach. Biochemical and Biophysical Research Communications, 410(3), 688–691. https://doi.org/10.1016/J.BBRC.2011.06.057
   PubMed Web of Science ®Google Scholar
• Majumder, R., & Mandal, M. (2022). Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an in silico docking and molecular dynamics simulation approach. Journal of Biomolecular Structure and Dynamics, 40(2), 696–711. https://doi.org/10.1080/07391102.2020.1817787
   PubMed Web of Science ®Google Scholar
• Manallack, D. T., Hughes, R. A., & Thompson, P. E. (2005). The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. Journal of Medicinal Chemistry, 48(10), 3449–3462. https://doi.org/10.1021/JM040217U
   PubMed Web of Science ®Google Scholar
• Menniti, F. S., Chappie, T. A., & Schmidt, C. J. (2020). PDE10A inhibitors—Clinical failure or window into antipsychotic drug action? Frontiers in Neuroscience, 14, 600178. https://doi.org/10.3389/FNINS.2020.600178/BIBTEX
   PubMed Web of Science ®Google Scholar
• Modestia, S. M., Malta De Sá, M., Auger, E., Trossini, G. H. G., Krieger, J. E., & Rangel-Yagui, C. D. O. (2019). Biased agonist TRV027 determinants in AT1R by molecular dynamics simulations. Journal of Chemical Information and Modeling, 59(2), 797–808. https://doi.org/10.1021/ACS.JCIM.8B00628/SUPPL_FILE/CI8B00628_SI_001.PDF
   PubMed Web of Science ®Google Scholar
• Nittinger, E., Inhester, T., Bietz, S., Meyder, A., Schomburg, K. T., Lange, G., Klein, R., & Rarey, M. (2017). Large-scale analysis of hydrogen bond interaction patterns in protein–ligand interfaces. Journal of Medicinal Chemistry, 60(10), 4245-57. https://doi.org/10.1021/ACS.JMEDCHEM.7B00101
   Google Scholar
• Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics, 52(12), 7182–7190. https://doi.org/10.1063/1.328693
   Web of Science ®Google Scholar
• Peng, T., Gong, J., Jin, Y., Zhou, Y., Tong, R., Wei, X., Bai, L., & Shi, J. (2018). Inhibitors of phosphodiesterase as cancer therapeutics. European Journal of Medicinal Chemistry, 150, 742–756. https://doi.org/10.1016/J.EJMECH.2018.03.046
   PubMed Web of Science ®Google Scholar
• Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066–4072. https://doi.org/10.1021/ACS.JMEDCHEM.5B00104/SUPPL_FILE/JM5B00104_SI_001.PDF
   PubMed Web of Science ®Google Scholar
• Rifai, E. A., Van Dijk, M., Vermeulen, N. P. E., Yanuar, A., & Geerke, D. P. (2019). A comparative linear interaction energy and MM/PBSA study on SIRT1–Ligand binding free energy calculation. Journal of Chemical Information and Modeling, 59(9), 4018–4033. https://doi.org/10.1021/ACS.JCIM.9B00609
   PubMed Web of Science ®Google Scholar
• Rodriguez, R. A., Yu, L., & Chen, L. Y. (2015). Computing protein-protein association affinity with hybrid steered molecular dynamics. Journal of Chemical Theory and Computation, 11(9), 4427–4438. https://doi.org/10.1021/ACS.JCTC.5B00340
   PubMed Web of Science ®Google Scholar
• Russo, S., Li, N., Lee, K., Xi, Y., Zhu, B., Gary, B., Ramirez, V., Gurpinar, E., Canzeroni, J., FajaRdo, A., Sigler, S., Piazza, J. T., Chen, X., Andrews, J., Li, Y., Eberhardt, B., Yet, L., Keeton, A., Grizzle, W. E., & Piazza, G. (2014). Phosphodiesterase 10, a novel target in colon cancer. Journal of Clinical Oncology, 32(3_suppl), 503–503. https://doi.org/10.1200/Jco.2014.32.3_suppl.503
   Web of Science ®Google Scholar
• Sack, J. S., Gao, M., Kiefer, S. E., Myers, J. E., Newitt, J. A., Wu, S., & Yan, C. (2016). Crystal structure of microtubule affinity-regulating kinase 4 catalytic domain in complex with a pyrazolopyrimidine inhibitor. Acta Crystallographica Section: F Structural Biology Communications, 72(2), 129–134. https://doi.org/10.1107/S2053230X15024747/TT5077SUP1.PDF
   PubMedGoogle Scholar
• Schlitter, J. (1993). Estimation of absolute and relative entropies of macromolecules using the covariance matrix. Chemical Physics Letters, 215(6), 617–621. https://doi.org/10.1016/0009-2614(93)89366-P
   Web of Science ®Google Scholar
• Schüttelkopf, A. W., & Van Aalten, D. M. F. (2004). PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica. Section D, Biological Crystallography, 60(Pt 8), 1355–1363. https://doi.org/10.1107/S0907444904011679
   PubMedGoogle Scholar
• Sharma, J., Kumar Bhardwaj, V., & Purohit, R. (2021). Recognition of distinct chemical molecules as inhibitors for KIT receptor mutants D816H/Y/V: A simulation approach. Journal of Molecular Liquids, 339, 116317. https://doi.org/10.1016/j.molliq.2021.116317
   Web of Science ®Google Scholar
• Singam, A., Ramaprasad, E., Raman Subramanian, S., Subramanian, V., Muvva, C., Singam, E. R. A., Sundar, S., Ab, R., & Subramanian, V. (2014). Structure-based virtual screening of novel, high-affinity BRD4 inhibitors. Molecular bioSystems, 10(9), 2384–2397. https://doi.org/10.1039/c4mb00243a
   PubMedGoogle Scholar
• Singh, R., Bhardwaj, V. K., Das, P., & Purohit, R. (2021). New ecdysone receptor agonists: A computational approach for rational discovery of insecticides for crop protection. Molecular Systems Design & Engineering, 6(11), 936–945. https://doi.org/10.1039/D1ME00047K
   Web of Science ®Google Scholar
• Singh, V. K., Chang, H. H., Kuo, C. C., Shiao, H. Y., Hsieh, H. P., & Coumar, M. S. (2017). Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors. Journal of Biomolecular Structure & Dynamics, 35(8), 1833–1848. https://doi.org/10.1080/07391102.2016.1196462
   PubMed Web of Science ®Google Scholar
• Siuciak, J. A., McCarthy, S. A., Chapin, D. S., Fujiwara, R. A., James, L. C., Williams, R. D., Stock, J. L., McNeish, J. D., Strick, C. A., Menniti, F. S., & Schmidt, C. J. (2006). Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function. Neuropharmacology, 51(2), 374–385. https://doi.org/10.1016/J.NEUROPHARM.2006.01.012
   PubMed Web of Science ®Google Scholar
• Tirado-Rives, J., & Jorgensen, W. L. (2008). Performance of B3LYP density functional methods for a large set of organic molecules. Journal of Chemical Theory and Computation, 4(2), 297–306. https://doi.org/10.1021/CT700248K/SUPPL_FILE/CT700248K-FILE002.PDF
   PubMed Web of Science ®Google Scholar
• Tung, Ngo, S., Vu, K. B., Minh, Bui, L., & Vu, V. V. (2019). Effective estimation of ligand-binding affinity using biased sampling method. ACS omega, 4(2), 3887-93. https://doi.org/10.1021/acsomega.8b03258
   Google Scholar
• Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., Berendsen, H., & J., C. (2005). GROMACS: Fast, flexible, and free: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/JCC.20291
   PubMed Web of Science ®Google Scholar
• Verhoest, P. R., Chapin, D. S., Corman, M., Fonseca, K., Harms, J. F., Hou, X., Marr, E. S., Menniti, F. S., Nelson, F., O’Connor, R., Pandit, J., Proulx-LaFrance, C., Schmidt, A. W., Schmidt, C. J., SuICiak, J. A., & Liras, S. (2009). Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. Journal of Medicinal Chemistry, 52(16), 5188–5196. https://doi.org/10.1021/JM900521K/SUPPL_FILE/JM900521K_SI_001.PDF
   PubMed Web of Science ®Google Scholar
• Wu, G., Robertson, D. H., Brooks, C. L., & Vieth, M. (2003). Detailed analysis of grid-based molecular docking: A case study of CDOCKER—A CHARMm-based MD docking algorithm. Journal of Computational Chemistry, 24(13), 1549–1562. https://doi.org/10.1002/JCC.10306
   PubMed Web of Science ®Google Scholar
• Xi, M., Sun, T., Chai, S., Xie, M., Chen, S., Deng, L., Du, K., Shen, R., & Sun, H. (2022). Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer’s disease. European Journal of Medicinal Chemistry, 232, 114170. https://doi.org/10.1016/J.EJMECH.2022.114170
   PubMed Web of Science ®Google Scholar
• Yadav, S., Pandey, S. K., Singh, V. K., Goel, Y., Kumar, A., & Singh, S. M. (2017). Molecular docking studies of 3-bromopyruvate and its derivatives to metabolic regulatory enzymes: Implication in designing of novel anticancer therapeutic strategies. PLoS One, 12(5), e0176403. https://doi.org/10.1371/journal.pone.0176403
   PubMed Web of Science ®Google Scholar
• Yang, Y., Zhang, S., Zhou, Q., Zhang, C., Gao, Y., Wang, H., Li, Z., Wu, D., Wu, Y., Huang, Y. Y., Guo, L., & Luo, H. B. (2020). Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. Acta Pharmaceutica Sinica. B, 10(12), 2339–2347. https://doi.org/10.1016/J.APSB.2020.04.003
   PubMed Web of Science ®Google Scholar
• Zhu, B., Lee, K., Canzoneri, J., Ramirez-Alcantara, V., Sigler, S., Gary, B., Butler, E., Keeton, A., Chen, X., Boyd, M., & Piazza, G. (2015). Abstract 4372: Phosphodiesterase 10A inhibition suppresses lung tumor cell growth by activating PKG to inhibit RAS and WNT signaling. Cancer Research, 75(15_Supplement), 4372–4372. https://doi.org/10.1158/1538-7445.AM2015-4372
   PubMedGoogle Scholar
• Zhu, B., Lindsey, A., Li, N., Lee, K., Ramirez-Alcantara, V., Canzoneri, J. C., Fajardo, A., Madeira da Silva, L., Thomas, M., Piazza, J. T., Yet, L., Eberhardt, B. T., Gurpinar, E., Otali, D., Grizzle, W., Valiyaveettil, J., Chen, X., Keeton, A. B., & Piazza, G. A. (2017). Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling. Oncotarget, 8(41), 69264–69280. https://doi.org/10.18632/ONCOTARGET.20566
   PubMedGoogle Scholar